|
| 37364816 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Ann Hepatol | 2024 |
| 38085944 | A Message from the Editors. | | 2024 |
| 37786277 | Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. | Aliment Pharmacol Ther | 2024 |
| 37088458 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 37088457 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 34999207 | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. | Clinical Gastroenterology and Hepatology | 2023 |
| 36368598 | Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. | J Hepatol | 2023 |
| 35513235 | Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. | Clinical Gastroenterology and Hepatology | 2023 |
| 36037274 | Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. | Hepatology | 2023 |
| 36349732 | Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. | Alimentary Pharmacology and Therapeutics | 2023 |
| 35811043 | The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. | Clinical Gastroenterology and Hepatology | 2023 |
| 35940513 | Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis. | Clin Gastroenterol Hepatol | 2023 |
| 36258033 | Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. | Nature Reviews Gastroenterology and Hepatology | 2023 |
| 36191268 | Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. | American Journal of Gastroenterology | 2023 |
| 36410554 | A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. | Journal of Hepatology | 2023 |
| 36402372 | The Protection Conferred by HSD17B13 rs72613567 on Hepatic Fibrosis Is Likely Mediated by Lowering Ballooning and Portal Inflammation. | Clinical Gastroenterology and Hepatology | 2023 |
| 36318027 | MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. | Radiology | 2023 |
| 37679433 | Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. | Nat Med | 2023 |
| 37604268 | Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study. | J Hepatol | 2023 |
| 37585204 | Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019. | JAMA Netw Open | 2023 |
| 37815451 | Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium. | Radiology | 2023 |
| 37901764 | Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials. | Liver Cancer | 2023 |
| 37718721 | Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. | | 2023 |
| 37885163 | Editorial: Can liver fat quantification stratify cardiovascular risk in type 2 diabetes? Authors' reply. | | 2023 |
| 37707388 | Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation. | | 2023 |
| 37694993 | MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses. | | 2023 |
| 37694808 | The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. | | 2023 |
| 37615850 | Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | Adv Ther | 2023 |
| 36521501 | Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. | | 2023 |
| 36716599 | Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. | | 2023 |
| 37406954 | Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: AÂ Prospective, Multicenter Study. | | 2023 |
| 37089038 | Meta-analysis: Prevalence of significant or advanced fibrosis in adults with alpha-1-antitrypsin deficiency. | | 2023 |
| 36513186 | A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. | J Hepatol | 2023 |
| 36711803 | The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis. | Res Sq | 2023 |
| 36511349 | A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. | | 2023 |
| 37144531 | Advances in the genetics of nonalcoholic fatty liver disease. | | 2023 |
| 37024213 | Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease. | | 2023 |
| 37021791 | Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. | Hepatology | 2023 |
| 37269117 | Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD. | | 2023 |
| 37268740 | Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. | | 2023 |
| 37203233 | Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study. | | 2023 |
| 36705333 | Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | | 2023 |
| 37013380 | Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. | | 2023 |
| 37453429 | Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply. | | 2023 |
| 37452591 | Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply. | | 2023 |
| 37069419 | Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease. | Hepatol Int | 2023 |
| 37127100 | Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. | Gastroenterology | 2023 |
| 36871771 | Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis. | Clin Gastroenterol Hepatol | 2023 |
| 36750244 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. | Gut | 2023 |
| 37121437 | An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. | J Hepatol | 2023 |